GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » Cyclically Adjusted PB Ratio

TECH (Bio-Techne) Cyclically Adjusted PB Ratio : 4.70 (As of Jun. 21, 2025)


View and export this data going back to 1989. Start your Free Trial

What is Bio-Techne Cyclically Adjusted PB Ratio?

As of today (2025-06-21), Bio-Techne's current share price is $49.87. Bio-Techne's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $10.60. Bio-Techne's Cyclically Adjusted PB Ratio for today is 4.70.

The historical rank and industry rank for Bio-Techne's Cyclically Adjusted PB Ratio or its related term are showing as below:

TECH' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.41   Med: 7.95   Max: 19.03
Current: 4.73

During the past years, Bio-Techne's highest Cyclically Adjusted PB Ratio was 19.03. The lowest was 4.41. And the median was 7.95.

TECH's Cyclically Adjusted PB Ratio is ranked worse than
77.89% of 683 companies
in the Biotechnology industry
Industry Median: 1.53 vs TECH: 4.73

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Bio-Techne's adjusted book value per share data for the three months ended in Mar. 2025 was $12.873. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $10.60 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bio-Techne Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Bio-Techne's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Cyclically Adjusted PB Ratio Chart

Bio-Techne Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.65 15.91 10.46 8.97 7.18

Bio-Techne Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.21 7.18 7.86 6.98 5.53

Competitive Comparison of Bio-Techne's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Bio-Techne's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Cyclically Adjusted PB Ratio falls into.


;
;

Bio-Techne Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Bio-Techne's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=49.87/10.60
=4.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Techne's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Bio-Techne's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=12.873/134.9266*134.9266
=12.873

Current CPI (Mar. 2025) = 134.9266.

Bio-Techne Quarterly Data

Book Value per Share CPI Adj_Book
201506 5.699 100.684 7.637
201509 5.634 100.392 7.572
201512 5.756 99.792 7.783
201603 5.733 100.470 7.699
201606 5.901 101.688 7.830
201609 6.001 101.861 7.949
201612 5.967 101.863 7.904
201703 6.080 102.862 7.975
201706 6.355 103.349 8.297
201709 6.414 104.136 8.311
201712 6.657 104.011 8.636
201803 7.047 105.290 9.031
201806 7.173 106.317 9.103
201809 7.337 106.507 9.295
201812 7.264 105.998 9.246
201903 7.578 107.251 9.534
201906 7.682 108.070 9.591
201909 7.708 108.329 9.600
201912 8.642 108.420 10.755
202003 8.468 108.902 10.492
202006 8.980 108.767 11.140
202009 9.321 109.815 11.452
202012 9.815 109.897 12.050
202103 9.905 111.754 11.959
202106 10.030 114.631 11.806
202109 10.436 115.734 12.167
202112 10.828 117.630 12.420
202203 10.916 121.301 12.142
202206 10.864 125.017 11.725
202209 11.159 125.227 12.023
202212 11.631 125.222 12.532
202303 12.010 127.348 12.725
202306 12.475 128.729 13.076
202309 12.616 129.860 13.108
202312 12.495 129.419 13.027
202403 12.785 131.776 13.091
202406 13.076 132.554 13.310
202409 13.461 133.029 13.653
202412 13.162 133.157 13.337
202503 12.873 134.927 12.873

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bio-Techne  (NAS:TECH) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Bio-Techne Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne Business Description

Industry
Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Executives
Kim Kelderman officer: Pres. Diagnostics & Genom 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Robert V Baumgartner director 5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416
John L Higgins director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Roeland Nusse director 473 TENNESSEE, PALO ALTO CA 94306
William Geist officer: PRESIDENT, PROTEIN SCIENCES 900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821
Charles R. Kummeth director, officer: Chief Executive Officer 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
Shane Bohnen officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Brenda S. Furlow officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Norman David Eansor officer: SVP Biotech 8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
James Hippel officer: Chief Financial Officer 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Joseph D Keegan director C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089
Julie L Bushman director 185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214
Rupert Vessey director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Alpna Seth director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Randolph C Steer director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413